Buyers widening their own doors: demand already secured, far-side receiving constraint now being cleared
The model's full reasoning — Q1 2017 call → NOWe need to determine if the transcript conveys a situation where demand is already in hand, the constraint is on the receiving side (counterparties' ability to absorb), and those counterparties are actively working on clearing that constraint, with the business mostly ahead of reported results. Let's analyze the transcript. Key points: - SPINRAZA launch: Biogen reported sales of over $47 million in Q1. The launch is gaining momentum. Biogen is working on expanding access, streamlining at centers, getting coverage approvals. They have 88 sites administering, 203 start forms. They are seeking coverage for Type 2 and 3. The demand is high. The constraint? The transcript says "Patient demand is high and physicians are motivated to prescribe SPINRAZA which are both important factors as the launch builds momentum." But the constraint is not explicitly described as the receiving side's capacity to absorb. It's more about launch momentum. However, there is mention of Biogen working on streamlining access, getting coverage approvals, etc. But is the constraint on the receiving side? The company (Ionis) is not the one delivering; Biogen is the partner. The demand is real, but the constraint is not clearly described as the counterparties' own ability to receive, install, etc. It's more about the launch process. Also, the business is already arriving (sales of $47M). So the associated business is already substantially delivered? Not necessarily, but the constraint is not clearly a far-side receiving limitation. - Volanesorsen: Akcea is preparing for launch. They are building commercial infrastructure, raising awareness, identifying patients. The constraint? They are working on identifying patients, but that's more about demand generation. The drug is not yet approved. So the business is not in hand; it's pending approval. So no. - IONIS-TTRRx: Phase III data imminent, but not yet reported. So no.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
MKC · Q2 2018 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive, install, etc., and those counterpartie...**NO** The transcript describes a situation where McCormick has already won shelf-space changes and distribution improvements from retailers (customers have accepted the recommendations), but implementation is delayed due to retailers' own operational reset windows and competitor product sell-through. This is framed as a temporary, ongoing industry practice rather than a binding constraint being actively cleared right now to unlock a meaningfully larger volume of already-secured business. Management presents it as part of their category-management progress with runway ahead, not as counterparties clearing a receiving-side bottleneck that is already underway and will drive the bulk of the upside.
BIIB · Q2 2017 → YESThe question is about whether management conveys that they already have secured demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties are already ...YES The transcript shows management conveying exactly this situation for SPINRAZA. Demand is already secured and arriving: “significant uptake in the U.S.” with “strong demand across patient types” and “roughly two third of patients treated to date having Type 2 or Type 3 SMA.” The binding constraint is on 60% of Type 2 patients who have had spinal surgery, creating intrathecal administration challenges on the receiving side.
BXP · Q1 2022 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties ...YES The transcript shows management conveying secured demand through signed leases totaling over 975,000 square feet on vacant space that have not yet commenced occupancy, plus an additional 1.3 million square feet in active negotiations and over 750,000 square feet in the development pipeline.